The RADCOMP (Randomized Trial of Proton vs. Photon Therapy for Patients with Breast Cancer Requiring Regional Nodal Irradiation) trial is one of the most significant clinical studies in radiation oncology in recent years, and its findings have direct implications for patients with breast cancer who need radiation to the chest wall and regional lymph nodes.

What Was Studied

The trial enrolled patients with locally advanced breast cancer requiring comprehensive regional nodal radiation. Half received standard photon (X-ray) radiation; the other half received proton beam therapy. The primary endpoint was major adverse cardiac events, heart attack, cardiac death, or need for coronary intervention.

Why It Matters

Breast cancer radiation can expose the heart to radiation dose, particularly when treating the left side or internal mammary lymph nodes. Proton therapy’s Bragg peak allows radiation to stop precisely at the target, substantially reducing the dose to the heart and lungs compared to conventional photon techniques.

The RADCOMP trial provides level-one evidence comparing these approaches head-to-head, something the field has long needed. Dr. Shannon MacDonald, one of the lead investigators, discussed the trial in detail on Episode 43 of The Cancer Project.

This is an introductory summary. Full trial results and updated analysis are available at ClinicalTrials.gov (NCT02603341).